Clinical Trial Registration: Looking Back and Moving Ahead
Authors: Christine Laine, Catherine De Angelis, Tony Delamothe, Jeffrey M. Drazen, Frank A. Frizelle, Charlotte Haug, Paul C. Hébert, Richard Horton, Sheldon Kotzin, Ana Marusic, Peush Sahni, Torben V. Schroeder, Harold C. Sox, Martin B. Van Der Weyden, Freek W.A. Verheugt
Journal: Annals of Internal Medicine (2007)

Editorials21 August 2007Clinical Trial Registration: Looking Back and Moving AheadFREEChristine Laine, MD, MPH, Catherine De Angelis, MD, MPH, Tony Delamothe, MD, Jeffrey M. Drazen, MD, Frank A. Frizelle, MBChB, MMedSc, Charlotte Haug, MD, PhD, MSc, Paul C. Hébert, MD, Richard Horton, FMedSci, Sheldon Kotzin, MLS, Ana Marusic, MD, PhD, Peush Sahni, MD, Torben V. Schroeder, MD, DMSc, Harold C. Sox, MD, Martin B. Van Der Weyden, MD, and Freek W.A. Verheugt, MDChristine Laine, MD, MPH, Catherine De Angelis, MD, MPH, Tony Delamothe, MD, Jeffrey M. Drazen, MD, Frank A. Frizelle, MBChB, MMedSc, Charlotte Haug, MD, PhD, MSc, Paul C. Hébert, MD, Richard Horton, FMedSci, Sheldon Kotzin, MLS, Ana Marusic, MD, PhD, Peush Sahni, MD, Torben V. Schroeder, MD, DMSc, Harold C. Sox, MD, Martin B. Van Der Weyden, MD, and Freek W.A. Verheugt, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-4-200708210-00166 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Key Summary PointsIn addition to accepting registration in any of the 5 existing registries, the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the WHO ICTRP. Registration in a partner register only is insufficient.The ICMJE will begin to implement the WHO definition of clinical trials for all trials that begin enrollment on or after 1 July 2008. This definition states that a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes."The ICMJE will not consider results posted in the same clinical trials registry in which the primary registration resides to be previous publication if the results are presented in the form of a brief, structured (<500 words) abstract or table.In 2005, the International Committee of Medical Journal Editors (ICMJE) initiated a policy requiring investigators to deposit information about trial design into an accepted clinical trials registry before the onset of patient enrollment (1). This policy aimed to ensure that information about the existence and design of clinically directive trials was publicly available, an ideal that leaders in evidence-based medicine have advocated for decades (2). The policy precipitated much angst among research investigators and sponsors, who feared that registration would be burdensome and would stifle competition. Yet, the response to this policy has been overwhelming. The ICMJE promised to reevaluate the policy in 2 years after implementation. Here, we summarize that reevaluation, specifically commenting on registries that meet the policy requirements, the types of studies that require registration, and the registration of trial results. As is always the case, the ICMJE establishes policy only for the 12 member journals (a detailed description of the ICMJE and its purpose is available at www.icmje.org), but many other journals have adopted our initial trial registration recommendations, and we hope that they will also adopt the modifications discussed in this update.The research community has embraced trial registration. Before the ICMJE policy, ClinicalTrials.gov, the largest trial registry at the time, contained 13 153 trials; this number climbed to 22 714 one month after the policy went into effect (3). In April 2007, the registry contained over 40 000 trials, with more than 200 new trial registrations occurring weekly (Zarin D. Personal communication). The 4 other registries that meet the ICMJE criteria have also grown as scores of journals have adopted the ICMJE clinical trials registration policy. In response to burgeoning registration, many investigators, sponsors, and government agencies have asked the ICMJE to recognize their local registries as databases that meet the policy. Fortunately, the World Health Organization's (WHO) International Clinical Trial Registry Platform (ICTRP), which was nascent when the ICMJE began to require trial registration, has matured rapidly and provides options for those that desire a wider array of registries. The ICTRP has taken the first steps toward developing a network of primary and partner registers that meet WHO-specified criteria (4). Primary registers are WHO-selected registers managed by not-for-profit entities that will accept registrations for any interventional trials, delete duplicate entries from their own register, and provide data directly to the WHO. Partner registers, which will be more numerous, will include registers that submit data to primary registers but limit their own register to trials in a restricted area (such as a specific disease, company, academic institution, or geographic region).The ICMJE strongly supports the WHO's efforts, through the ICTRP, to develop a coordinated process for identifying, gathering, deduplicating, and searching trials from registries around the world, thus eventually providing a 1-stop search portal for those seeking information about clinical trials. In addition to the 5 existing registries, the ICMJE will now also accept registration in any of the primary registers that participate in the WHO ICTRP. Because it is critical that trial registries are independent of for-profit interests, the ICMJE policy requires registration in a WHO primary register rather than solely in a partner register, since for-profit entities manage some partner registers. As previously, trial registration with missing or uninformative fields for the minimum data elements is inadequate (1).Initially, the ICMJE required registration of all clinically directive trials, which it defined as "any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome" (1). In May 2005, the ICMJE clarified this definition to exclude preliminary trials designed to study pharmacokinetics or major unknown toxicity (phase I trials) (5). However, the ICMJE recognizes the potential benefit of having information about preliminary trials in the public domain, because these studies can guide future research or signal safety concerns. Consequently, the ICMJE is expanding the definition of the types of trials that must be registered to include these preliminary trials and adopts the WHO's definition of clinical trial: "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes" (4). Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. As previously, purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration. The ICMJE member journals will start to implement the expanded definition of clinically directive trials for all trials that begin enrollment on or after 1 July 2008. Those who are uncertain whether their trial meets the expanded ICMJE definition should err on the side of registration if they wish to seek publication in an ICMJE journal.Over the time during which registration of trial methods has become common practice, several forces have begun advocating for registration of trial results. We recognize that the climate for results registration will probably change dramatically and unpredictably over coming years. For the present, the ICMJE will not consider results posted in the same primary clinical trials register in which the initial registration resides as previous publication if the results are presented in the form of a brief, structured (<500 words) abstract or table. The ICMJE favors a standard abstract format for results reporting, and the CONSORT (Consolidated Standards for the Reporting of Trials) group's forthcoming guidelines for abstracts related to trials may be one such option. The ICMJE believes that parties interested in results registration should consider requiring the deposition of such an abstract in the registry 24 months after closure of data collection if results are not published in a peer-reviewed venue by that time. The registered abstract should either cite any related full, peer-reviewed publications or include a statement that indicates that the report has not yet been published in a peer-reviewed journal. Researchers should be aware that editors may consider more detailed deposition of trial results in publicly available registries to be prior publication. When submitting a paper, authors should fully disclose to editors all posting in registries of results of the same or closely related work.Three years ago, trials registration was the exception; now it is the rule. Registration facilitates the dissemination of information among clinicians, researchers, and patients, and it helps to assure trial participants that the information that accrues as a result of their altruism will become part of the public record. The WHO's global efforts towards comprehensive trials registration and the ICMJE's requirements for registration aim to increase public trust in medical science.Christine Laine, MD, MPH, Senior Deputy Editor, Annals of Internal MedicineRichard Horton, FMedSci, Editor, The LancetCatherine D. DeAngelis, MD, MPH, Editor-in-Chief, JAMAJeffrey M. Drazen, MD, Editor-in-Chief, New England Journal of MedicineFrank A. Frizelle, MBChB, MMedSc, Editor-in-Chief, The New Zealand Medical JournalFiona Godlee, MBBChir, BSc, Editor-in-Chief, BMJCharlotte Haug, MD, PhD, MSc, Editor-in-Chief, Norwegian Medical JournalPaul C. Hébert, MD, MHSc, Editor-in-Chief, Canadian Medical Association JournalSheldon Kotzin, MLS, Executive Editor, MEDLINE, National Library of MedicineAna Marusic, MD, PhD, Editor, Croatian Medical JournalPeush Sahni, MS, PhD, Representative and Past President, World Association of Medical EditorsTorben V. Schroeder, MD, DMSc, Editor, Journal of the Danish Medical AssociationHarold C. Sox, MD, Editor, Annals of Internal MedicineMartin B. Van Der Weyden, MD, Editor, The Medical Journal of AustraliaFreek W.A. Verheugt, MD, Deputy Editor, Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine)Christine Laine, MD, MPHSenior Deputy Editor, Annals of Internal MedicineRichard Horton, FMedSciEditor, The LancetCatherine D. DeAngelis, MD, MPHEditor-in-Chief, JAMAJeffrey M. Drazen, MDEditor-in-Chief, New England Journal of MedicineFrank A. Frizelle, MBChB, MMedScEditor-in-Chief, The New Zealand Medical JournalFiona Godlee, MBBChir, BScEditor-in-Chief, BMJCharlotte Haug, MD, PhD, MScEditor-in-Chief, Norwegian Medical JournalPaul C. Hébert, MD, MHScEditor-in-Chief, Canadian Medical Association JournalSheldon Kotzin, MLSExecutive Editor, MEDLINE, National Library of MedicineAna Marusic, MD, PhDEditor, Croatian Medical JournalPeush Sahni, MS, PhDRepresentative and Past President, World Association of Medical EditorsTorben V. Schroeder, MD, DMScEditor, Journal of the Danish Medical AssociationHarold C. Sox, MDEditor, Annals of Internal MedicineMartin B. Van Der Weyden, MDEditor, The Medical Journal of AustraliaFreek W.A. Verheugt, MDDeputy Editor, Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine)References1. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Accessed at www.icmje.org/clin_trial.pdf on 22 May 2007. Google Scholar2. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986;4:1529-41. [PMID: 3760920] CrossrefMedlineGoogle Scholar3. Zarin DA, Tse T, Ide NC. Trial Registration at ClinicalTrials.gov between May and October 2005. N Engl J Med. 2005;353:2779-87. [PMID: 16382064] CrossrefMedlineGoogle Scholar4. World Health Organization. Internation Clinical Trials Registry Platform. Accessed at www.who.int/ictrp/about/details/en/index.html on 22 May 2007. Google Scholar5. International Committee of Medical Journal Editors. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Accessed at www.icmje.org/clin_trialup.htm on 22 May 2007. Google Scholar Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Christine Laine, MD, MPH; Catherine De Angelis, MD, MPH; Tony Delamothe, MD; Jeffrey M. Drazen, MD; Frank A. Frizelle, MBChB, MMedSc; Charlotte Haug, MD, PhD, MSc; Paul C. Hébert, MD; Richard Horton, FMedSci; Sheldon Kotzin, MLS; Ana Marusic, MD, PhD; Peush Sahni, MD; Torben V. Schroeder, MD, DMSc; Harold C. Sox, MD; Martin B. Van Der Weyden, MD; Freek W.A. Verheugt, MDAffiliations: Disclaimer: Dr. Sahni's affiliation as a representative and past president of the World Association of Medical Editors (WAME) does not imply endorsement by WAME member journals that are not part of the ICMJE.Disclosures: Employment: Dr. Godlee was previously editorial director of Current Controlled Trials, which owns the ISRCTN (International Standard Randomised Controlled Trial Number) trials register. Mr. Kotzin is employed by the National Library of Medicine, which produces ClinicalTrials.gov; Mr. Kotzin is not responsible for activities or policies regarding ClinicalTrials.gov. Expert testimony: F. Godlee. Other: R. Horton (Co-Chair, WHO ICTRP Scientific Advisory Group); J.M. Drazen (member, WHO ICTRP Scientific Advisory Group); H.C. Sox (member, WHO ICTRP Scientific Advisory Group); M.B. Van Der Weyden (member, government advisory committee for the Australian and New Zealand Clinical Trials Registry). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAvailability of Results of Trials Studying Pancreatic Adenocarcinoma over the Past 10 YearsAvailability of results of interventional studies assessing colorectal cancer from 2013 to 2020Clinical Practice Guidelines Registry: Toward Reducing Duplication, Improving Collaboration, and Increasing TransparencyYaolong Chen, MD, MSc, Gordon H. Guyatt, MD, MSc, Zachary Munn, PhD, Ivan D. Florez, MD, MSc, PhD, Ana Marušić, MD, PhD, Susan L. Norris, MD, MPH, MSc, Tamara Kredo, MBChB, MMed, PhD, and Amir Qaseem, MD, PhD, MHASPIRIT 2013 Bildirisi: Klinik Deneyler İçin Standart Protokol Maddelerinin TanımlanmasıPhytotherapy of Hypertension: An Updated OverviewRéglementation de la recherche médicale en FranceAssessment of transparent and reproducible research practices in the psychiatry literatureAn empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogsPhylotocol: Promoting Transparency and Overcoming Bias in PhylogeneticsThe Role and Importance of Clinical Trial Registries and Results DatabasesWhy clinical trial outcomes fail to translate into benefits for patientsTRIPS and disclosure of clinical information: An intellectual property perspective on data sharingDel dataWhen are clinical trials registered? An analysis of prospective versus retrospective registrationClinical research data sharing: what an open science world means for researchers involved in evidence synthesisStatistical and data reporting guidelines for the European Journal of Cardio-Thoracic Surgery and the Interactive CardioVascular and Thoracic SurgeryDesign and execution of clinical trials in orthopaedic surgeryRegistration Rates, Adequacy of Registration, and a Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials Published in Surgery JournalsTrust but Verify: Trial Registration and Determining Fidelity to the ProtocolDeborah A. Zarin, MD and Tony Tse, PhDThe need for registration of preclinical studiesSPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical TrialsAn-Wen Chan, MD, DPhil, Jennifer M. Tetzlaff, MSc, Douglas G. Altman, DSc, Andreas Laupacis, MD, Peter C. Gøtzsche, MD, DrMedSci, Karmela Krleža-Jerić, MD, DSc, Asbjørn Hróbjartsson, PhD, Howard Mann, MD, Kay Dickersin, PhD, Jesse A. Berlin, ScD, Caroline J. Doré, BSc, Wendy R. Parulekar, MD, William S.M. Summerskill, MBBS, Trish Groves, MBBS, Kenneth F. Schulz, PhD, Harold C. Sox, MD, Frank W. Rockhold, PhD, Drummond Rennie, MD, and David Moher, PhDReferencesReferencesComparison of Arthroplasty Trial Publications After Registration in ClinicalTrials.govShould preclinical studies be registered?The Role and Importance of Clinical Trial Registries and Results DatabasesReporting of Clinical Trials: Publication, Authorship, and Trial RegistrationCompleteness and Changes in Registered Data and Reporting Bias of Randomized Controlled Trials in ICMJE Journals after Trial Registration PolicyQuality assurance in gastroenterology: QA in research, and research in QADistribution of Country of Origin in Studies Used in Cochrane ReviewsThe RegistrarReporting of Methodologic Information on Trial Registries for Quality Assessment: A Study of Trial Records Retrieved from the WHO Search PortalBidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?Update on Registration of Clinical Trials in ClinicalTrials.govUten registrering, ingen publisering!Diabetes Care : Moving (a Little) in the Winds of ChangeRegistro dos ensaios clínicos 21 August 2007Volume 147, Issue 4Page: 275-277KeywordsClinical trialsGlobal healthLibrariesObservational studiesPharmacokineticsPrevention, policy, and public healthProspective studiesPublic policySafety studiesToxicity ePublished: 21 August 2007 Issue Published: 21 August 2007 PDF downloadLoading ...